Wednesday, 14 October 2026European Markets

VAN DE VELDE And KID Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(VIANEWS) - VAN DE VELDE (VAN.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Cyclical sector.

Financial Asset Price Forward Dividend Yield Return on Equity
VAN DE VELDE (VAN.BR) €35.25 7.47% 22.83%
KID (KID.OL) kr140.00 6.8% 24.25%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VAN DE VELDE (VAN.BR)

7.47% Forward Dividend Yield and 22.83% Return On Equity

Van de Velde NV, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear in Europe and North America. The company operates through two segments, business to business and direct to consumer. It offers its products under the PrimaDonna, Marie Jo, and Andres Sarda brands. The company provides its products through its retail networks, website, and department stores, as well as independent retail and e-tail partners, franchisees, and marketplaces. The company was founded in 1919 and is headquartered in Schellebelle, Belgium. Van de Velde NV is a subsidiary of Van de Velde Holding NV.

Earnings Per Share

As for profitability, VAN DE VELDE has a trailing twelve months EPS of €2.77.

PE Ratio

VAN DE VELDE has a trailing twelve months price to earnings ratio of 12.73. Meaning, the purchaser of the share is investing €12.73 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.83%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on May 2, 2024, the estimated forward annual dividend rate is 2.4 and the estimated forward annual dividend yield is 7.47%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VAN DE VELDE's stock is considered to be oversold (<=20).

More news about VAN DE VELDE.

2. KID (KID.OL)

6.8% Forward Dividend Yield and 24.25% Return On Equity

Kid ASA, together with its subsidiaries, operates as a home textile retailer in Norway, Sweden, Finland, and Estonia. It designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. The company provides its products under the Kid, Hemtex, Dekosol, Nordun, and Premium Collection brands. It also offers logistics services. The company was formerly known as Nordisk Tekstil Holding AS and changed its name to Kid ASA. Kid ASA was founded in 1937 and is headquartered in Lier, Norway.

Earnings Per Share

As for profitability, KID has a trailing twelve months EPS of kr5.88.

PE Ratio

KID has a trailing twelve months price to earnings ratio of 23.81. Meaning, the purchaser of the share is investing kr23.81 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.25%.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is 49.6% and 14.4%, respectively.

More news about KID.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com